Helicobacter pylori (H. pylori) is a bacterium with a distinctive spiral shape that colonizes the stomach lining and is closely associated with various gastrointestinal ailments, including gastritis, peptic ulcers, and even stomach cancer. The importance of immunoassays in the context of H. pylori detection cannot be overstated. These laboratory techniques, based on the specific binding properties of antibodies, offer a range of advantages. They exhibit an exceptional level of sensitivity, capable of identifying even minuscule amounts of H. pylori antigens or antibodies in various patient samples like blood, stool, or breath. This sensitivity ensures that infections can be diagnosed accurately, even in their early stages. Furthermore, immunoassays are highly specific, distinguishing H. pylori from other microorganisms, thus minimizing the risk of false-positive results. Moreover, their non-invasive nature is particularly valuable, as they eliminate the need for more invasive procedures, such as endoscopy, for diagnosis. Additionally, immunoassays play a vital role in monitoring the effectiveness of H. pylori eradication therapy over time. The timely and precise detection facilitated by immunoassays is instrumental in guiding treatment decisions, managing gastrointestinal diseases, and, ultimately, preventing severe complications associated with H. pylori infections, enhancing patient outcomes, and reducing the risk of long-term complications, such as gastric cancer.